Due to its high frequency of alterations in breast malignancy, its causative role in tumorigenesis/tumor progression and its role in conferring resistance to diverse therapies, MYC is a highly attractive target for new anti-cancer therapies for this disease [19–21]. The gene discussed is MYC; the disease is neoplasm.